Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Enveric Biosciences Inc (ENVB) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Enveric Biosciences IncTrade
Regeneron Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

Enveric Biosciences Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Enveric Biosciences Inc trades at $1.35 (market cap $5.32M), while Regeneron Pharmaceuticals Inc trades at $675.02 (market cap $69.66B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 13094× Enveric Biosciences Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.57% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.

ENVBREGN
Market Cap
$5.32M$69.66B
Sector
HealthHealth
52-Week High
$17.40$812.27
52-Week Low
$1.28$542.52
Enterprise Value
$408.82K$63.61B
Dividend Yield
0.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Enveric Biosciences Inc

No Aura AI signal available yet.

Regeneron Pharmaceuticals Inc

Regeneron (REGN) trades at $656.11, down 1.05% on the day, with a bullish technical signal and strong fundamentals. The stock shows robust profitability with a 29.65% net income margin and has beaten EPS estimates for three consecutive quarters. Recent positive news includes FDA and EMA acceptance of cemdisiran for gMG treatment and selection for an FDA manufacturing review pilot program, reinforcing growth prospects.

Outlook remains positive with a consensus price target of $764.50, implying 16.5% upside. Key opportunities include earnings momentum and regulatory advancements, while risks involve competitive pressures and dependence on key drug performance. Institutional sentiment is strongly bullish with 69% buy ratings, though legal investigations and market volatility warrant monitoring.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Enveric Biosciences Inc

Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.

Read more on ENVB

About Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases

Read more on REGN